GFAP and frontotemporal dementia: In a clinical trial comparing GFAP levels within serum samples taken from participants experiencing cognitive and/or behavioral impairment or FTD versus those diagnosed only with ALS, the results showed significant variation [88]; however, no difference was noted among various types of clinical presentations for individuals diagnosed with only ALS regarding GFAP levels within their serum samples [88].